Otonomy announced the signing of a co-promotion agreement with Mission Pharmacal Company that provides Mission with an exclusive right to promote OTIPRIO for acute otitis externa in pediatrician and primary care physician offices as well as urgent care clinics in the United States. Financial terms for the multi-year agreement were not disclosed; however, Otonomy will receive an annual co-promotion fee and reimbursement of a proportion of product support expenses, and retain a share of gross profits from the sale of OTIPRIO to Mission’s accounts. Otonomy retains all commercial rights for other customer segments for AOE and use of OTIPRIO in all other indications including ongoing sales for use during pediatric ear tube surgery.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.